nidНефрология и диализNephrology and Dialysis1680-44222618-9801Российское диализное обществоnid-1335Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESПрименение заместительной почечной терапии в комплексном лечении тяжелого острого панкреатитаПодкорытоваО. Л.PodkorytovaO. L.noemail@neicon.ruТомилинаН. А.TomilinaN. A.noemail@neicon.ruБикбовБ. Т.BikbovB. T.noemail@neicon.ruВторенкоВ. И.VtorenkoV. I.noemail@neicon.ruШиринскийВ. Г.ShirinskyV. G.noemail@neicon.ruЛоктевВ. В.LoktevV. V.noemail@neicon.ruФедороваН. Д.FedorovaN. D.noemail@neicon.ruЧураИ. С.ChuraI. S.noemail@neicon.ruРодниковС. Е.RodnikovS. E.noemail@neicon.ruМосковский городской нефрологический центр, Городская клиническая больница № 52. Кафедра нефрологии ФПДО МГМСУ; г. МоскваRussian Federation200819062025103-4226233Copyright © Подкорытова О.Л., Томилина Н.А., Бикбов Б.Т., Вторенко В.И., Ширинский В.Г., Локтев В.В., Федорова Н.Д., Чура И.С., Родников С.Е., 20252025Подкорытова О.Л., Томилина Н.А., Бикбов Б.Т., Вторенко В.И., Ширинский В.Г., Локтев В.В., Федорова Н.Д., Чура И.С., Родников С.Е.Podkorytova O.L., Tomilina N.A., Bikbov B.T., Vtorenko V.I., Shirinsky V.G., Loktev V.V., Fedorova N.D., Chura I.S., Rodnikov S.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephro.ru/jour/article/view/1335

Целью данного исследования явилось проведение ретроспективного анализа эффективности заместительной почечной терапии (ЗПТ) в комплексном лечении тяжелого острого панкреатита (ТОП), протекающего с синдромами системного воспалительного ответа и полиорганной недостаточности/дисфункции. Мы анализировали результаты лечения 55 больных (14 женщин и 41 мужчина) в возрасте от 22 до 72 лет (в среднем 43,5 ± 16,4), лечившихся в отделениях реанимации и интенсивной терапии Московской городской клинической больницы № 52 за период 01.01.2000 по 31.12. 2006 г. Все больные имели мультиорганную дисфункцию с числом пораженных органов от 2 до 5 (медиана 4 (3; 4)) и находились на заместительной почечной терапии. Заместительная почечная терапия может быть с успехом применена в комплексном лечении тяжелого острого панкреатита, при условии обеспечения дозы диализа не менее 35 мл/кг/ч. Независимыми факторами риска смерти больных с ТОП, являются тяжесть состояния, оцениваемая по шкалам APACHE II, SAPS II и доза диализа менее 35 мл/кг/ч.

The aim of the study to analyze retrospectively the efficiency of renal replacement therapy in treatment of severe acute pancreatitis complicated with systemic inflammation and multiorgan dysfunction. The results of treatment of 55 patients (14 F, 41 M) 22 to 72 years old (average 43,5 ± 16,4) treated in intensive care department of Moscow City Hospital No. 52 from 01.01.2000 to 31.12.2006 were analyzed. All patients had multiorgan dysfunction, with 2 to 5 organs (median 4 (3; 4)) involved and receiving renal replacement therapy. Renal replacement therapy can be successfully used in complex treatment of severe acute pancreatitis provided the dialysis dose of at least 35 ml/kg/h. Independent risk factors of lethality in these patients are - severity estimated according to APACHE II SAPS II scales, and dialysis dose of at least 35 ml/kg/h.

острый панкреатиттяжелое течениесиндром системного воспаленияполиорганная недостаточностьприменение почечно-заместительной терапииReferencesAbosaif N.Y. et al. The outcome of ARF in the intensive care unit according to RIFLE: model applicability, sensitivity, and predictability. Am J Kidney Dis 2005; 46: 1038-1048.Abosaif N.Y. et al. The outcome of ARF in the intensive care unit according to RIFLE: model applicability, sensitivity, and predictability. Am J Kidney Dis 2005; 46: 1038-1048.Bassi C., Falconi M., Valerio A. Identification of pancreatic infection. In Buchler M (ed) Acute Pancreatitis: Novel Concepts in Biology and Therapy. Blackwell Science, Boston; 1999; 277-282.Bassi C., Falconi M., Valerio A. Identification of pancreatic infection. In Buchler M (ed) Acute Pancreatitis: Novel Concepts in Biology and Therapy. Blackwell Science, Boston; 1999; 277-282.Beck D.H. et al. External validation of the SAPS II, APACHE II, APACHE III prognostic models in South England: a multicenter study. Intensive Care Med 2003; 29: 249-256.Beck D.H. et al. External validation of the SAPS II, APACHE II, APACHE III prognostic models in South England: a multicenter study. Intensive Care Med 2003; 29: 249-256.Bellomo R., Ronco C., Kellum J.A., Mehta R.L., Palevsky P. ARF: definition, outcome measures, animal models, fluid therapy and information technology needs. The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; R204-12.Bellomo R., Ronco C., Kellum J.A., Mehta R.L., Palevsky P. ARF: definition, outcome measures, animal models, fluid therapy and information technology needs. The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; R204-12.Blinzler L., Sieberth H.G., Stummvoll H.K. Conservative treatment of server necrotizing pancreatitis using early continuous veno-venous HF. Contrib Nephrol 1991; 93: 234-236.Blinzler L., Sieberth H.G., Stummvoll H.K. Conservative treatment of server necrotizing pancreatitis using early continuous veno-venous HF. Contrib Nephrol 1991; 93: 234-236.Cole L., Bellomo R., Journois D. et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002; 30: 100-106.Cole L., Bellomo R., Journois D. et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002; 30: 100-106.D’Egidio A. et al. Surgical strategies in treatment of pancreatic necrosis and infection, Br J Surg 2002; 78: 133-137.D’Egidio A. et al. Surgical strategies in treatment of pancreatic necrosis and infection, Br J Surg 2002; 78: 133-137.En-Qiang Mao et al. Effect of time interval for hemofiltration on the prognosis of severe acute pancreatitis. World J Gastroenterol Feb 2003; 15; 9 (2): 373-376.En-Qiang Mao et al. Effect of time interval for hemofiltration on the prognosis of severe acute pancreatitis. World J Gastroenterol Feb 2003; 15; 9 (2): 373-376.Gehbart C. et al. Changes in therapy of sever acute pancreatitis. Chirurg 1994; 65: 33-40.Gehbart C. et al. Changes in therapy of sever acute pancreatitis. Chirurg 1994; 65: 33-40.Guice R.S., Oldham K.T., Johnson K.J. et al. Pancreatitis-induced acute lung injury. An ARDS model. Ann Surg 1988; 208: 71-77.Guice R.S., Oldham K.T., Johnson K.J. et al. Pancreatitis-induced acute lung injury. An ARDS model. Ann Surg 1988; 208: 71-77.Hao Wang, Wei-Qin Li, Wei Zhou, Ning Li, Jie-Shou Li. Clinical effects of continuous high volume hemofiltration on severe acute pancreatitis complicated with multiple organ dysfunction syndrome. World J Gastroenterology 2003; Sept 9 (9): 2096-2099.Hao Wang, Wei-Qin Li, Wei Zhou, Ning Li, Jie-Shou Li. Clinical effects of continuous high volume hemofiltration on severe acute pancreatitis complicated with multiple organ dysfunction syndrome. World J Gastroenterology 2003; Sept 9 (9): 2096-2099.Le Gall J.R. et al. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270: 2957-2963.Le Gall J.R. et al. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993; 270: 2957-2963.Mergener R. Baillie J. Acute pancreatitis. Br Med J 1998; 316: 44-48.Mergener R. Baillie J. Acute pancreatitis. Br Med J 1998; 316: 44-48.Norman J. The role of cytokines in the pathogenesis of acute pancreatitis. Am J Surg 1998; 175: 76-83.Norman J. The role of cytokines in the pathogenesis of acute pancreatitis. Am J Surg 1998; 175: 76-83.Ronco C., Bellomo R., Homel P. et al. Effects of different doses in CVVH on outcomes of ARF: A prospective randomized trial. Lancet 2000; 355: 26-30.Ronco C., Bellomo R., Homel P. et al. Effects of different doses in CVVH on outcomes of ARF: A prospective randomized trial. Lancet 2000; 355: 26-30.Schmid S.W. et al. The role of infection in acute pancreatitis. Gut 1999; 45: 311-316.Schmid S.W. et al. The role of infection in acute pancreatitis. Gut 1999; 45: 311-316.Schmidt J., Werner J. Acute pancreatitis: reliable and prospective conservative therapy. Langenbecks Arch Chir Suppl Congressed 1998; 115: 434-438.Schmidt J., Werner J. Acute pancreatitis: reliable and prospective conservative therapy. Langenbecks Arch Chir Suppl Congressed 1998; 115: 434-438.Wang H. et al. Amelioration of hemodynamics and oxygen metabolism by continuous venovenous hemofiltration in experimental porcine pancreatitis. World J Gastroenterol 2005 Jan 7; 11 (1): 127-131.Wang H. et al. Amelioration of hemodynamics and oxygen metabolism by continuous venovenous hemofiltration in experimental porcine pancreatitis. World J Gastroenterol 2005 Jan 7; 11 (1): 127-131.Wang H. et al. Clinical effects continuous high volume hemofiltration on acute pancreatitis complicated with multiple organ dysfunction syndrome. World J Gastroenterology, Sep 2003; 9 (9): 2096-2099.Wang H. et al. Clinical effects continuous high volume hemofiltration on acute pancreatitis complicated with multiple organ dysfunction syndrome. World J Gastroenterology, Sep 2003; 9 (9): 2096-2099.Yang Z. et al. Effect of early hemofiltration on pro- and anti-inflammatory responses and multiple organ failure in severe acute pancreatitis. J Huazhong Univ Sci Technolog Med Sci 2004; 24 (5): 456-459.Yang Z. et al. Effect of early hemofiltration on pro- and anti-inflammatory responses and multiple organ failure in severe acute pancreatitis. J Huazhong Univ Sci Technolog Med Sci 2004; 24 (5): 456-459.Yang Z. et al. Protective effect CVVH and organ damage in patients with severe acute pancreatitis. World J Gastroenterology 2004; Apr 16 (4): 232-234.Yang Z. et al. Protective effect CVVH and organ damage in patients with severe acute pancreatitis. World J Gastroenterology 2004; Apr 16 (4): 232-234.

The authors declare that there are no conflicts of interest present.